The selective active peptide developed by Yu et al. (VIVIT) can significantly and more selectively inhibits calcium/calmodulin-activated NFATc1, NFATc2, and NFATc3 dephosphorylation and NFATc2 nuclear translocation, indicating that it may become a promising drug to study the exact role of the NFAT response in atherosclerosis and subsequent targeted therapy. Here, NFATC3 is linked to atherosclerosis.